

Receipt 1MAGET

Docket No.: A7542.0000/P001-E

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Ginette Serrero

Application No.: 09/824,647

Confirmation No.: 2662

Filed: April 4, 2001

Art Unit: 1642

For: 88KDA TUMORIGENIC GROWTH

FACTOR AND ANTAGONISTS

Examiner: M. Yu

REQUEST FOR CORRECTED FILING RECEIPT

Filing Receipt Corrections
Office of Initial Patent Examination
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicant hereby requests that a corrected Filing Receipt be issued in the aboveidentified patent application. The official Filing Receipt received by Applicant, a copy of which is attached hereto, has omitted part of the Domestic Priority data as claimed by applicant. The Domestic Priority data as claimed by applicant should read as follows:

This application is a Divisional of 09/456,886 12/8/1999, which is a divisional of 08/991,862 12/16/1997, Which is a Continuation-In-Part of 08/863,079 5/23/1997.

Applicant additionally requests that all pertinent U.S. Patent and Trademark

Application No.: 09/824,647 Docket No.: A7542.0000/P001-E

Office records relating to the subject application be changed to reflect this correction.

Dated: April 9, 2004

Respectfully submitted,

James W. Brady, Jr.

Registration No.: 32,115

Jeremy A. Cubert

Registration No.: 40,399

DICKSTEIN SHAPIRO MORIN & OSHINSKY LLPThomas J. D'Amico

2101 L Street NW

Washington, DC 20037-1526Registration

No.: 37,131 (202) 785-9700

Attorneys for Applicant



Washington, DC 20037-1526

United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023I
www.uspto.gov

OC000000008171651

APPLICATION NUMBER FILING DATE **GRP ART UNIT** FIL FEE REC'D ATTY.DOCKET.NO **DRAWINGS** TOT CLAIMS IND CLAIMS A7542.0000/P001 09/824,647 04/04/2001 17 12 CONFIRMATION NO. 2662 James W. Brady, Jr. ATED FILING RECEIPT **DICKSTEIN SHAPIRO MORIN & OSHINSI** 2101 L. Street NW

Date Mailed: 05/23/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Ginette Serrero, Ellicott City, MD;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A DIV OF 09/456,886 12/08/1999 WHICH IS A DIV OF 08/991,862 12/16/1997 PAT 6,309,826 Which is a CIP OF 08/863,079 5/23/1997

Foreign Applications

If Required, Foreign Filing License Granted 03/22/2002

Projected Publication Date: 08/29/2002

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

88kDa tumorigenic growth factor and antagonists

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).